Constitutional Court to Review GC Biopharma Complaint Against Supreme Court Ruling
First case accepted under new judicial reform law allowing complaints against finalized court decisions
L'essentiel
The Constitutional Court of South Korea will hear a complaint from GC Biopharma regarding a fine for bid-rigging, marking the first time the court has accepted such a case under new judicial reform legislation.
Résumé généré par IA
Pourquoi c'est important
A new judicial reform law in South Korea recently allowed for constitutional complaints to be filed against finalized court rulings.
The Constitutional Court said Tuesday it will hear biopharmaceutical company GC Biopharma Corp.'s constitutional complaint against a court ruling over a fine levied by the anti-trust regulator.
It marks the first court ruling to be reviewed by the court since the recent enactment of a judicial reform law that allows constitutional complaints to be filed against finalized rulings.
Since the law took effect last month, the court has received 525 complaints, rejecting 265 of the 266 cases that underwent preliminary review.
The biopharmaceutical company is disputing a Supreme Court ruling that upheld the Fair Trade Commission's fine for rigging vaccine purchase bids between April 2017 and January 2019.
The company had filed an administrative suit against the regulator's decision, but the Supreme Court ultimately rejected it in February without formal deliberation.
The company filed the constitutional complaint against the ruling last month, arguing the Supreme Court denied its right to a trial.
À surveiller
Perspective IA — des possibilités, pas des certitudes
The Constitutional Court will issue a landmark ruling on the scope of judicial review.
Probable · En quelques mois
Questions ouvertes
- What are the specific legal arguments the Constitutional Court will focus on?
- How will this ruling affect the 265 previously rejected complaints?
